Capital Fund Management (CFM)’s TG Therapeutics TGTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,900	Closed	-$593K	–	2538
2025 Q4	$593K	Buy	19,900 +4,100	+26%	+$134K	﹤0.01%	2175
2025 Q3	$571K	Sell	15,800 -9,600	-38%	-$316K	﹤0.01%	2272
2025 Q2	$914K	Sell	25,400 -15,900	-38%	-$592K	﹤0.01%	2031
2025 Q1	$1.63M	Sell	41,300 -240,600	-85%	-$8.1M	﹤0.01%	1501
2024 Q4	$8.49M	Sell	281,900 -38,700	-12%	-$1.11M	0.02%	824
2024 Q3	$7.5M	Sell	320,600 -103,800	-24%	-$2.27M	0.02%	833
2024 Q2	$7.55M	Sell	424,400 -38,400	-8%	-$613K	0.02%	797
2024 Q1	$7.04M	Sell	462,800 -681,300	-60%	-$10.9M	0.02%	889
2023 Q4	$19.5M	Buy	1,144,100 +723,100	+172%	+$8.4M	0.05%	458
2023 Q3	$3.52M	Buy	421,000 +151,300	+56%	+$2.11M	0.01%	1115
2023 Q2	$6.7M	Buy	269,700 +72,400	+37%	+$1.87M	0.03%	724
2023 Q1	$2.97M	Buy	+197,300	New	+$3M	0.01%	929
2021 Q4	–	Sell	-13,900	Closed	-$463K	–	1855
2021 Q3	$463K	Buy	+13,900	New	+$430K	﹤0.01%	1391

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Capital Fund Management (CFM)'s TGTX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its TG Therapeutics (TGTX) stake by 195% in Q1 2026, buying an estimated $2.22M and bringing the position to 112,684 shares worth $3.74M. The position accounts for 0.02% of the portfolio, ranked #1043.

Capital Fund Management (CFM) first reported a position in TGTX in Q4 2020 and has held it in 10 quarters since. The position peaked at $6.92M in Q2 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Capital Fund Management (CFM) held 112,684 shares of TG Therapeutics worth $3.74M as of Q1 2026.
Capital Fund Management (CFM) bought 74,530 TG Therapeutics shares in Q1 2026, an estimated $2.22M.
TG Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1043 holding.
Capital Fund Management (CFM) first reported a position in TG Therapeutics in Q4 2020 and has held it in 10 quarters since.
Capital Fund Management (CFM)'s TG Therapeutics position peaked at $6.92M in Q2 2024.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.